A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma

Facet Biotech18 sites in 1 country120 target enrollmentSeptember 2001

ConditionsAsthma

DrugsDaclizumab

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Asthma
Sponsor: Facet Biotech
Enrollment: 120
Locations: 18
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.

Registry

clinicaltrials.gov

Start Date

September 2001

End Date

December 2003

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Facet Biotech

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•History of asthma for 6 or more months
•History of chronic persistent asthma requiring daily high dose inhaled corticosteroid for 3 or more months prior to enrollment